MedTrace Logo

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

NCT03433807 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-04-21

No results posted yet for this study

Summary

The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.

Conditions

Interventions

DRUG

Idebenone

900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)

Sponsors & Collaborators

  • Santhera Pharmaceuticals

    lead INDUSTRY

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433807 on ClinicalTrials.gov